Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?
Abstract
Introduction: Biosimilars present a considerable potential to reduce costs related to clinical management allowing health-care providers to reinvest this money, leading to a wider access to an effective biological treatment with monoclonal antibodies (mAb). Infliximab biosimilars have already been incorporated in daily clinical practice and are currently used in all indications for which the reference product (RP) was approved. Areas covered: In...
Paper Details
Title
Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?
Published Date
May 23, 2019
Volume
25
Issue
1
Pages
7 - 12
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History